IDEAYA Biosciences Terminates Material Definitive Agreement
Ticker: IDYA · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, termination
TL;DR
IDEAYA terminated a big deal, filing 8-K on Dec 12.
AI Summary
IDEAYA Biosciences, Inc. announced on December 9, 2025, the termination of a material definitive agreement. The company, incorporated in Delaware, filed this 8-K report on December 12, 2025, detailing the event. The specific details of the agreement and the reasons for its termination are not elaborated upon in the provided text.
Why It Matters
The termination of a material definitive agreement can significantly impact a company's operations, partnerships, and financial outlook, requiring careful investor scrutiny.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement often signals underlying issues or strategic shifts that could pose financial or operational risks.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- December 9, 2025 (date) — Date of earliest event reported
- December 12, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
FAQ
What was the nature of the material definitive agreement that was terminated?
The provided text does not specify the nature of the material definitive agreement that was terminated.
When did the termination of the material definitive agreement become effective?
The filing indicates that December 9, 2025, is the date of the earliest event reported, which is the termination of the agreement.
What are the potential financial implications of this termination for IDEAYA Biosciences?
The filing does not provide details on the potential financial implications of the termination.
Were there any specific clauses or conditions that led to the termination?
The provided text does not contain information regarding the specific clauses or conditions that led to the termination.
Has IDEAYA Biosciences entered into any new agreements following this termination?
The filing is an 8-K reporting the termination and does not mention any subsequent agreements.
Filing Stats: 863 words · 3 min read · ~3 pages · Grade level 15.6 · Accepted 2025-12-12 16:05:41
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- d800445d8k.htm (8-K) — 25KB
- 0001193125-25-317541.txt ( ) — 137KB
- idya-20251209.xsd (EX-101.SCH) — 3KB
- idya-20251209_lab.xml (EX-101.LAB) — 18KB
- idya-20251209_pre.xml (EX-101.PRE) — 11KB
- d800445d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements Certain statements contained herein are forward-looking statements, including, but not limited to, statements related to the transfer of IDE275 and IDE705 clinical programs from GSK to the Company and the cash runway guidance. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company's preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including the Company's programs' early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing or commercialization of drug products, the outcome of pricing, coverage and reimbursement negotiations with third-party payors for the Company's products, the Company's ability to successfully establish, protect and defend its intellectual property, and other matters that could affect the sufficiency of existing cash to fund operations. The Company undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see the Company's Annual Report on Form 10-K dated February 18, 2025 and any current and periodic reports filed or furnished with the Securities and Exchange Commission.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: December 12, 2025 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer